/
Other
Atrophy
59
Pipeline Programs↗
101
Active Trials↗
60
Companies Involved↗
Atrophy is a moderately active landscape with 59 programs across 60 companies. The most active players are Roche. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 113
Phase 218
Phase 312
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
39 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 90% of 59 pipeline programs.
Analysis
Trial Status
285
clinical trials
Completed140 · 49%
Recruiting50 · 18%
Active, not recruiting29 · 10%
Terminated24 · 8%
Not yet recruiting19 · 7%
Unknown status8 · 3%
Other15 · 5%
Clinical Trials
Trial Activity
285 trials
Expansion Study of ALT001 in Patients With Multiple System Atrophy
Recruiting·—·Phase 1·NCT07476352·60 enrolled
The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type
Recruiting·—·Phase 1·NCT07514923·20 enrolled
Page 1 of 19
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)